Member Profile

ARCE Therapeutics specializes in developing proprietary gene-modified cellular therapies, including chimeric antigen receptor T-cell (CAR-T) and NK-cell (CAR-NK) cell therapies for finding cures for malignancies in human hematological and solid tumors. The idea is to rewire human’s own immune system with a targeting “GPS” for fighting cancers; for example, CAR-T/NK therapy involves genetic modifications of patients’ T-cells followed by ex vivo cell expansion and re-infusion back into the patients. Despite the remarkable outcomes and FDA approvals of CD19 and BCMA CAR-Ts in treating blood cancers, there are challenges to be addressed in reducing toxicity, tackling solid tumors, and lowering the cost of such amazing living drugs. ARCE’s CAR-T/NK cell therapy products are developed via three technologies, DashCARTM, MaxCARTM, and OneCARTM. Each technology tackles key challenges to meet these unmet medical needs. We are committed to originating state-of-the-art products of new generation CAR-T / CAR-NK cell therapies with high potency, safety, and durability, and thus to achieve a sustained improved response capable of conquering human diseases. We focus on the needs of patients to achieve the goals of effective treatment of diseases and reasonable medical cost through our “innovative immune cell therapy”. We collaborate with partners globally on converging various technologies and platforms and expect to significantly shorten the manufacturing process of CAR immune cells, as well as to expand CAR immune cell therapy from autologous to allogeneic administration to benefit more patients.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2020 ARCE therapeutics Inc. was estabilsed.
   2020 Trademarks DashCARTM, MaxCARTM, and OneCARTM granted in Taiwan
   2020 Healthcare EXPO Taiwan
   2020 Trademarks DashCAR, MaxCAR, and OneCAR granted in EU
   2021 Participated SelectUSA Tech Summit